EGFR and cancer: The REFRACT study conducted a retrospective analysis of data from 12 Chinese cancer research institutions, and the results showed that among patients with locally advanced EGFR mutation NSCLC, first-line use of RT+TKI± chemotherapy was associated with better PFS and OS (6).